Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CNR1 | P21554 | 1/20 | 0.56 |
| ▸ | CNR2 | P34972 | 1/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.53 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18546023 | 1.00 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2TRPV1DUSP3 | |
| SCHEMBL15054267 | 1.00 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2TRPV1DUSP3 | |
| SCHEMBL29605889 | 1.00 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2TRPV1DUSP3 | |
| SCHEMBL18546025 | 1.00 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2TRPV1DUSP3 | |
| SCHEMBL18546028 | 1.00 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2TRPV1DUSP3 | |
| SCHEMBL16510791 | 1.00 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2TRPV1DUSP3 | |
| SCHEMBL6261092 | 0.98 | ALDH1A1 (0.58) | ALDH1A1CNR1CNR2TRPV1DUSP3 | |
| SCHEMBL12474184 | 0.98 | ALDH1A1 (0.58) | ALDH1A1CNR1CNR2TRPV1DUSP3 | |
| SCHEMBL237980 | 0.96 | ALDH1A1 (0.56) | ALDH1A1CNR1CNR2TRPV1 | |
| SCHEMBL10354079 | 0.96 | ALDH1A1 (0.59) | ALDH1A1CNR1CNR2TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9643916-B2 | Low molecular weight cationic lipids for oligonucleotide delivery | SIRNA THERAPEUTICS, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-20170050917-A1 | NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | SIRNA THERAPEUTICS, INC. (US) | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050917-A1 | NOVEL LOW MOLECULAR WEIGHT CATIONIC LIPIDS FOR OLIGONUCLEOTIDE DELIVERY | LDLR, APOB, NPC1L1 | ALDH1A1 4239/4885CNR1 1891/4885CNR2 2703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.